Disease · MONDO_0007959

medulloblastoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. medulloblastoma. Diseases, record MONDO_0007959. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007959

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: medulloblastoma; Open Targets
Open Targets ID: MONDO_0007959; Open Targets
Other names: brain medulloblastoma, cerebellum embryonal neoplasm, medulloblastoma, autosomal recessive, autosomal dominant, somatic mutation, medulloblastoma, desmoplastic, autosomal recessive, autosomal dominant, somatic mutation, medulloblastoma, malignant, medulloblastoma, somatic, medulloblastomas; Open Targets
Disease Ontology: DOID:0050902; Disease Ontology
Disease Ontology: DOID:0060104; Disease Ontology
MeSH: D008527; MeSH
NCI Thesaurus: C3222; NCI Thesaurus
Orphanet: ORPHA:616; Orphanet
Highest stage of its drugs: Approval, for 1 of its 97 drugs, from DailyMed and FDA; Open Targets

Drugs97

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARMUSTINE	CHEMBL513	Small molecule	Approval	DailyMed and FDA	2	0	0	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	33	33	33	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	25	25	25	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 3	ClinicalTrials.gov	22	22	22	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	20	20	20	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 3	ClinicalTrials.gov	17	17	17	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets
LOMUSTINE	CHEMBL514	Small molecule	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	13	13	13	Drugs and targets
THIOTEPA	CHEMBL671	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets

1 to 10 of 97

See all 97 drugs

Targets192

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 192

See all 192 targets

Trials108

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00085735	Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma	Phase 3	549	2017-06-14	Medulloblastoma	CISPLATIN, CYCLOPHOSPHAMIDE, LOMUSTINE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00085202	Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor	Phase 3	416	2014-02-27	Brain and Central Nervous System Tumors	CISPLATIN, CYCLOPHOSPHAMIDE, FILGRASTIM, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00392327	Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET	Phase 3	379	2020-08-07	Anaplastic Medulloblastoma, Medulloblastoma	CARBOPLATIN, CISPLATIN, CYCLOPHOSPHAMIDE, ISOTRETINOIN, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT00602667	Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma	Phase 2	293	2019-01-30	Brain and Central Nervous System Tumors	CYCLOPHOSPHAMIDE, METHOTREXATE, TOPOTECAN, VINBLASTINE	Its record names the disease	ClinicalTrials.gov
NCT03130959	A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies	Phase 2	166	2021-04-01	Various Advanced Cancer	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT04447755	A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)	Phase 2	127	2023-10-04	Relapsed or Refractory Solid Tumors	LENVATINIB	Its record names the disease	ClinicalTrials.gov
NCT00601003	Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma	Phase 2	112	2022-12-29	Neuroblastoma, Medulloblastoma	CYCLOPHOSPHAMIDE, NIFURTIMOX, TOPOTECAN	Its record names the disease	ClinicalTrials.gov
NCT01217437	Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors	Phase 2	108	2019-09-13	Central Nervous System Neoplasm, Pineoblastoma, Recurrent Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Medulloblastoma, Refractory Peripheral Primitive Neuroectodermal Tumor	BEVACIZUMAB, IRINOTECAN HYDROCHLORIDE, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00357500	Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer	Phase 2	101	2014-09-09	Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific	CELECOXIB, CYCLOPHOSPHAMIDE, ETOPOSIDE, FENOFIBRATE, THALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00381797	Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma	Phase 2	97	2013-01-15	Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma	BEVACIZUMAB, IRINOTECAN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 108

See all 108 trials

Comparisons in its trials17

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Average-Risk Group vs High-Risk Group: serious adverse events	17 of 269	17 of 144	413	NCT00085202	Trial comparisons
Arm I (Temozolomide, Irinotecan Hydrochloride) vs Arm II (Temozolomide, Irinotecan Hydrochloride, Bevacizumab): deaths from any cause	48 of 54	42 of 52	106	NCT01217437	Trial comparisons
Arm I (Temozolomide, Irinotecan Hydrochloride) vs Arm II (Temozolomide, Irinotecan Hydrochloride, Bevacizumab): serious adverse events	9 of 54	12 of 52	106	NCT01217437	Trial comparisons
Temozolomide + Irinotecan for Medulloblastoma vs Temozolomide + Irinotecan for High-Grade Glioma: serious adverse events	31 of 66	5 of 17	83	NCT00404495	Trial comparisons
Arm I (Patients Treated Without Methotrexate (MTX)) vs Arm II (Patients Treated With MTX): Number of Participants With Chronic Primary Hypothyroidism/Subclinical Compensatory HypothyroidismHypothyroidism/Subclinical Compensatory Hypothyroidism	3 of 39	5 of 38	77	NCT00336024	Trial comparisons
Arm I (Patients Treated Without Methotrexate (MTX)) vs Arm II (Patients Treated With MTX): Number of Participants With Chronic Low Somatomedin C	2 of 39	5 of 38	77	NCT00336024	Trial comparisons
Arm I (Patients Treated Without Methotrexate (MTX)) vs Arm II (Patients Treated With MTX): Number of Participants With Secondary Malignancies	1 of 39	0 of 38	77	NCT00336024	Trial comparisons
Arm I (Patients Treated Without Methotrexate (MTX)) vs Arm II (Patients Treated With MTX): Number of Participants With Chronic Diabetes Insipidus	1 of 39	1 of 38	77	NCT00336024	Trial comparisons
Arm I (Patients Treated Without Methotrexate (MTX)) vs Arm II (Patients Treated With MTX): deaths from any cause	18 of 39	15 of 38	77	NCT00336024	Trial comparisons
Arm I (Patients Treated Without Methotrexate (MTX)) vs Arm II (Patients Treated With MTX): Number of Participants With Chronic Central Hypothyroidism	1 of 39	1 of 38	77	NCT00336024	Trial comparisons

1 to 10 of 17

See all 17 comparisons in its trials

Papers from its trials52

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37883081	RESULT	1	PubMed
32719487	RESULT	1	PubMed
30332335	RESULT	1	PubMed
23894304	RESULT	1	PubMed
22665539	RESULT	1	PubMed
21636711	RESULT	1	PubMed
19533657	RESULT	1	PubMed
18623206	RESULT	1	PubMed
18447671	RESULT	1	PubMed
18309946	RESULT	1	PubMed

1 to 10 of 52

See all 52 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007959

GET https://conductscience.org/api/diseases/v1/MONDO_0007959/drugs?page=2

API reference For AI assistants